Payment & Shipping Terms:
|Product Name:||Fluconazole||CAS Number:||86386-73-4|
|Molecular Formula:||C13H12F2N6O||Molecular Weight:||306.27|
|Grade:||Pharmaceutical Grade||Appearance:||White Crystal Or Crystalline|
White crystalline powder Fluconazole pharmaceutical raw material 86386-73-4
Alias: Diflucan; fluconazole; Triflucan
CAS number: 86386-73-4
Molecular formula: C13H12F2N6O
Molecular weight: 306.27
Appearance:white crystal or crystalline
Fluconazole is an antifungal medication that is administered orally or intravenously. It is used to treat a variety of fungal infections, especially Candida infections of the vagina,mouth, throat, and bloodstream. It is also used to prevent infections in people with weak immune systems, including those with neutropenia due to cancer chemotherapy, transplant patients, and premature babies. Its mechanism of action involves interfering with synthesis of the fungal cell membrane.
Fluconazole is a first-generation triazole antifungal medication. It differs from earlier azole antifungals (such as ketoconazole) in that its structure contains a triazole ring instead of an imidazole ring. While the imidazole antifungals are mainly used topically, fluconazole and certain other triazole antifungals are preferred when systemic treatment is required because of their improved safety and predictable absorption when administered orally.
Fluconazole's spectrum of activity includes most Candida species (but not Candida krusei or Candida glabrata), Cryptococcus neoformans, some dimorphic fungi, and dermatophytes, among others. Common uses include:
1)The treatment of non-systemic Candida infections of the vagina,throat, and mouth.
2)Certain systemic Candida infections in people with healthy immune systems, including infections of the bloodstream, kidney, or joints. Other antifungals are usually preferred when the infection is in the heart or central nervous system, and for the treatment of active infections in people with weak immune systems.
3)The prevention of Candida infections in people with weak immune systems, such as those neutropenic due to cancer chemotherapy, those with advanced HIV infections, transplant patients, and premature infants.
4)As a second-line agent for the treatment of cryptococcal meningoencephalitis, a fungal infection of the central nervous system.
|Test Item||Limt||Test Results|
|Appearance||White or almost White,Hygroscople,Crystalline Powder||Conforms|
|Solubility||Slightly Soluble in water,freely soluble in methanol,soluble in acetone||Complies|
|Appearance of solution||The solution is clear and colorless||Complies|
|Related Substances %||IMPURITY A≤0.4
|Heavy Metals %||≤0.001||<0.001|
|Loss on Drying %||≤0.5||0.18|
|Sulphated Ash %||≤0.1||<0.1|
|Assay (On Dry Basis) %||99.0-101.0||99.68|
|Granule Size||180 Micron Max||Conforms|
|Conclusion||Conforms to EP5.6|